Clinical trials: Neck Cancer
Head and Neck Cancer Squamous Cell Carcinoma
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.
The objective of this research is to evaluate the efficacy of the new drug INCA33890 compared to the standard reference treatment, pembrolizumab. The study treatment is INCA33890. The reference treatment is pembrolizumab.
- Trial name
- TRACE (NCT07876414)
- Testing
- INCA33890, Pembrolizumab
- Volunteers
- 78 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Cancer of the Head and Neck, Xerostomia
The Effectiveness of a Thyme and Honey Spray for Oral Toxicities
Aim: To evaluate the effectiveness of thymus honey on radiation induced-oral mucositis and xerostomia. Background: Oral mucositis and xerostomia are two of the most severe side effects that head and neck cancer patients confront…
- Conditions
- Cancer of the Head and Neck, Xerostomia, Oral Mucositis, Radiation Toxicity
- Trial name
- HONEY (NCT04880148)
- Testing
- Thyme and Honey-based oral spray
- Where
- 2 sites in Cyprus
- Volunteers
- 200 people
- Sponsor
- Cyprus University of Technology
Cervical Cancer, Precancerous/Nonmalignant Condition
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia
RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia.
- Trial name
- IRB 1996-0189 (NCT00003598)
- Testing
- tretinoin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Head and Neck Cancer
Iodine I 131 in Treating Patients With Thyroid Cancer
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
- Trial name
- NCT00416949
- Testing
- Patient-specific dosimetry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
This is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally…
- Trial name
- NEOCRTE2601 (NCT07751055)
- Testing
- Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, PET/CT
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
PET/CT follow up for Head and Neck Squamous Cell Carcinoma The following is a presentation of a prospective protocol, named PET/CT follow up for Head and Neck Squamous Cell Carcinoma (PET Follow), including patients who have…
- Trial name
- PET Follow (NCT05707078)
- Testing
- Neck dissection
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Comparison of AIRVO High Flow Oxygen Therapy With Standard Care for Prevention of PPCs After Major H&N Surgery
Patients undergoing major head and neck surgery often develop breathing difficulties as a result of build up of sputum and difficulty taking deep breaths.
- Trial name
- NCT03828578
- Testing
- High flow oxygen therapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cardiff and Vale University Health Board
Locally Recurrent Head and Neck Cancer
Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours
The aim of the present trial is to assess the prospective results of protocol-based interstitial pulsed-dose-rate (PDR) brachytherapy with interstitial hyperthermia (iHT) in a group of selected patients where salvage surgery with…
- Trial name
- HyBT-H&N (NCT03238378)
- Testing
- Brachytherapy, Hyperthermia
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Esophagus Cancer, Gastric Cancer
Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy.
The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help…
- Conditions
- Esophagus Cancer, Gastric Cancer, Leak, Anastomotic, Complication
- Trial name
- PROFUGO (NCT05390684)
- Testing
- audit of complications, prospective data collection
- Where
- Spain
- Volunteers
- 800 people
- Sponsor
- Hospital Universitario La Fe
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or…
- Trial name
- NCT00003748
- Testing
- irinotecan hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Oral Mucositis
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
The goal of this study is to describe the effect of photobiomodulation (PBM) on the incidence and severity of oral mucositis in post-operative oral cancer patients receiving radiotherapy +/- chemotherapy.
- Trial name
- PBM (NCT07387978)
- Testing
- photobiomodulation
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Stage II Esophageal Cancer, Stage III Esophageal Cancer
A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer
Neoadjuvant chemoradiotherapy(Neo-CRT) plus surgery has been regarded as a standard of care for patients with resectable locally advanced oesophageal cancer.
- Trial name
- NCT02959385
- Testing
- Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT…
- Trial name
- NCT06020885
- Testing
- Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Esophageal Cancer
Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy
The clinical value of intraoperative nerve monitoring (IONM) in thoracoscopic esophagectomy remains uncertain. The aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their…
- Trial name
- NCT05199168
- Testing
- intraoperative nerve monitoring
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer
Effect of Pre-operative Virtual Visits on Patients With Head and Neck Cancer Undergoing Surgery
Patients with head and neck cancer often undergo complex surgeries requiring significant care post-operatively. This presents considerable psychosocial challenges in addition to their need to physically recover from a large…
- Trial name
- NCT06094621
- Testing
- Survey
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
- Trial name
- NCT01613768
- Testing
- eribulin mesylate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Cervical Cancer
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally…
- Trial name
- NCT06333821
- Testing
- Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT)
- Volunteers
- 460 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.